ATHENS, Ohio--(BUSINESS WIRE)--Diagnostic HYBRIDS has received funding through the Biomedical Research Commercialization Program (BRCP) to develop more sensitive and affordable assays for the monitoring of patients infected with Human Immunodeficiency Virus (HIV) and/or Hepatitis C Virus (HCV) and to produce vaccines against influenza virus. The BRCP is part of the Third Frontier Project, a push by Ohio lawmakers to bring biotechnology and related businesses into the state of Ohio.
